Skip to main content

Stryker Value Stock - Dividend - Research Selection

Stryker

ISIN: US8636671013 , WKN: 864952

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


How The Stryker (SYK) Narrative Is Shifting As Analysts Rework Targets And Risks

2026-04-21
Stryker’s fair value estimate has been trimmed slightly, with the price target moving from US$425.08 to US$419.11, a reduction of about 1.4%. This kind of modest reset aligns with recent Street commentary, where analysts are balancing long term optimism about Stryker’s growth drivers with more caution on near term valuation and risk. This has led to target tweaks rather than sweeping rating changes. As you read on, you will see how these small shifts fit into the broader analyst narrative and...

[Latest] Global Surgical Drill Bits Market Size/Share Worth USD 540 Million by 2035 at a 5.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

2026-04-21
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Surgical Drill Bits Market size & share revenue was valued at approximately USD 316 Million in 2025 and is expected to reach USD 333 Million in 2026 and is expected to reach around USD 540 Million by 2035, at a CAGR of 5.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are DePuy Synthes (Johnson & Johnson)

Stryker's Q1 2026 Earnings: What to Expect

2026-04-20
Stryker is ready to release its fiscal first-quarter earnings this month, and analysts project a single-digit profit growth.

EY on the current state of the medtech industry

2026-04-20
OEMs continue to prioritise high-growth segments of the medtech industry such as pulsed-field ablation (PFA), while conflict in the Middle East is impacting IPO activity.

GEHC vs. SYK: Which Stock Is the Better Value Option?

2026-04-17
GEHC vs. SYK: Which Stock Is the Better Value Option?

Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)

2026-04-16
PHILADELPHIA, April 16, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC advises shareholders of Stryker Corporation about an investigation into Stryker's Board of Directors ...

US FDA Stryker updates use instructions for patient-fitted tmj implants

2026-04-15
Stryker Corp:US FDA: Stryker updates use instructions for patient-fitted tmj implants US FDA: As of Dec 4, Stryker reported one serious injury & no deaths associated with patient-fitted tmj...

Stryker Updates Use Instructions For Patient-Fitted TMJ Implants; As Of Dec 4, Stryker Reported One Serious Injury & No Deaths Associated With Patient-Fitted TMJ Implants Issue

2026-04-15
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/reconstruction-prosthesis-correction-stryker-updates-use-instructions-patient-fitted-tmj-implants

Truist Securities Maintains Hold on Stryker, Lowers Price Target to $380

2026-04-15
Truist Securities analyst Richard Newitter maintains Stryker (NYSE:SYK) with a Hold and lowers the price target from $395 to $380.

AIP to acquire Avanos Medical in $1.27B go-private deal

2026-04-15
Avanos Medical generated $701.2 million last year from sectors where it competes with Boston Scientific, Medtronic and Stryker.